You are here

Non-invasive efficient brain delivery of Prussian Blue for treatment of Alzheimer disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44AG066386-02
Agency Tracking Number: R44AG066386
Amount: $1,459,774.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: PAS18-187
Timeline
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-01
Award End Date (Contract End Date): 2022-08-31
Small Business Information
5611 ROOSEVELT ST
Bethesda, MD 20817-6739
United States
DUNS: 809594661
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 IRVING WEINBERG
 (301) 346-7944
 inweinberg@gmail.com
Business Contact
 IRVING WEINBERG
Phone: (301) 346-7944
Email: inweinberg@gmail.com
Research Institution
N/A
Abstract

Abstract
Direct brain injection of radical-scavenging dyes (e.g. Prussian blue) prevents and cures
Alzheimer’s disease in animal models. In human tests of orally administered blue dyes,
however, reaching therapeutic concentration levels in the brain has not been achievable.
Our published rodent experiments have shown that helical magnetic fields can drill
magnetic nanorods from the nose into the brain with very high efficiency. Rodent studies
have shown no toxicity after 30-days of particle implantation. In the first phase of this fast-
track project, we will validate that our magnetic drilling methods can deliver therapeutic
levels of blue dye in the brain non-invasively. In the second phase we will verify that this
delivery method improves cognition in a rodent model of Alzheimer disease (AD).
Accomplishment of this goal will pave the way to human studies, aided by already-
committed investors in the project and by experienced academic partners with whom we
have worked for over a decade.Narrative
Direct brain injection of radical-scavenging dyes (e.g. Prussian blue) prevents and cures
Alzheimer’s disease in animal models. In human tests of orally administered blue dyes,
however, reaching therapeutic concentration levels in the brain has not been achievable.
Our published rodent experiments have shown that helical magnetic fields can drill
magnetic nanorods from the nose into the brain with very high efficiency. In the first phase
of this fast-track project, we will validate that our magnetic drilling methods can deliver
therapeutic levels of blue dye in the brain non-invasively. In the second phase we will
verify that this delivery method improves cognition in a rodent model of Alzheimer disease
(AD). Accomplishment of this goal will pave the way to human studies, aided by already-
committed investors in the project and by experienced academic partners with whom we
have worked for over a decade.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government